How Biotech Startups Are Using Conjugation Technologies

In this episode of Biotech Business with Fexingo, Lucas and Luna explore the emerging field of antibody-drug conjugates (ADCs) and how startups are leveraging conjugation chemistry to improve cancer therapies. They discuss the case of Mersana Therapeutics, which uses a novel linker platform to attach potent toxins to antibodies, and compare it to traditional chemotherapy. The hosts explain how ADC technology works, why linker stability matters, and what the market opportunity looks like. They also touch on the broader trend of drug delivery platforms and how large pharma is partnering with smaller biotechs. A clear, jargon-light look at a fast-moving corner of biotech. #AntibodyDrugConjugates #ADCs #MersanaTherapeutics #BiotechStartups #DrugDelivery #CancerTherapy #LinkerTechnology #ConjugationChemistry #TargetedTherapy #Chemotherapy #PharmaPartnerships #Payload #MonoclonalAntibodies #ClinicalTrials #BusinessAndTechnology #FexingoBusiness #BusinessPodcast #BiotechBusiness Keep every episode free: buymeacoffee.com/fexingo